Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 46 points (-0.4%) at 12,524 as of Thursday, Nov. 15, 2012, 12:05 PM ET. The NYSE advances/declines ratio sits at 826 issues advancing vs. 2,151 declining with 91 unchanged. The Health Services industry currently sits down 0.7% versus the S&P 500, which is down 0.5%. On the negative front, top decliners within the industry include Mindray Medical International ( MR), down 2.5%, Cooper Companies ( COO), down 1.5%, HCA Holdings ( HCA), down 1.2% and Thermo Fisher Scientific ( TMO), down 0.9%. TheStreet Ratings group would like to highlight 5 stocks pushing the industry lower today: 5. Hologic ( HOLX) is one of the companies pushing the Health Services industry lower today. As of noon trading, Hologic is down $0.23 (-1.2%) to $19.63 on light volume Thus far, 709,921 shares of Hologic exchanged hands as compared to its average daily volume of 2.2 million shares. The stock has ranged in price between $19.52-$19.90 after having opened the day at $19.83 as compared to the previous trading day's close of $19.86. Hologic Inc. develops, manufactures, and supplies diagnostic, medical imaging systems, and surgical products for the healthcare needs of women. The company operates in four segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. Hologic has a market cap of $5.4 billion and is part of the health care sector. The company has a P/E ratio of 14.7, below the S&P 500 P/E ratio of 17.7. Shares are up 15.6% year to date as of the close of trading on Wednesday. Currently there are 16 analysts that rate Hologic a buy, no analysts rate it a sell, and 3 rate it a hold. TheStreet Ratings rates Hologic as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and weak operating cash flow. Get the full Hologic Ratings Report now.